Calling all LLS volunteers! 📣 ​

Bag some exclusive LLS goodies this #NationalVolunteerWeek ! 🎁🌟 Just tell us in one sentence why you said YES! to volunteering with LLS for a chance to win! You support our goal of changing the future of #BloodCancer treatment and care. 🥳

When a passion for the earth AND a vision for an earth without #BloodCancer meet 🌎🌱♻️☀️👉 bit.ly/3w2U3LK #EarthDay

When your teacher asks you to write an essay, this is what they mean 🌎🌱♻️☀️👉 bit.ly/4d5AiE2 #EarthDay

The last comment though! 🎯 We’re giving a SHOUT OUT to our incredible LLS Volunteers for their incredible dedication to supporting #BloodCancer patients and their families! 📣❤️🙌 You're the heart and soul of our mission, and we couldn't be more grateful for your exceptional

What do blood cancer, scholarships, and the Mediterranean Sea have in common? The answer 👉 bit.ly/3UtQdF5 #EarthDay 🌱♻️☀️

🎙️🎧 Tune in this #AMLWorldAwarenessDay as we dive into groundbreaking research on acute myeloid #leukemia (AML). Join Dr. Elie Traer, Dr. Karin Rodland, and Dr. Lee Greenberger as they unveil an exciting collaboration between OHSU News, Pacific Northwest National Laboratory, and LLS' Beat AML Master Clinical

Spread love and support on #AMLWorldAwarenessDay ! ❤️👇 Join us in spreading awareness and HOPE this year!

❤️ Our investment in game-changing breakthroughs like our Beat AML® Master Clinical Trial is improving outcomes. Because of this trial, some patients with a prognosis of

🚨 PROGRESS! 🚨 The U.S. FDA recently approved two CAR T-cell therapies for earlier treatment of adults with multiple myeloma. Before these approvals, patients had to have received at least four different types of treatment before they were eligible for CAR T-cell therapy.

“CAR

Exciting research coming right up! 🗣️ Meet Paolo Strati, MD – a dedicated lymphoma researcher at MD Anderson Cancer Center in Houston. Dr. Strati is on a mission to revolutionize B-cell lymphoma treatment.

Dr. Strati presented data from an LLS-funded study at one of the world’s premiere

🚨 PROGRESS! 🚨 The U.S. FDA recently approved two CAR T-cell therapies for earlier treatment of adults with multiple myeloma. Before these approvals, patients had to have received at least four different types of treatment before they were eligible for CAR T-cell therapy.

“CAR

Join us & Jeremy Abramson, MD as we talk all things Hodgkin #lymphoma in our upcoming webcast! 🔬🥼 Learn more about treatment advances & options, side-effect management, self-monitoring & relationships with your healthcare team. Secure your spot 👉 bit.ly/3JjP9Nk

Joining forces for a brighter tomorrow! 🌟 We’re grateful for the unwavering passion of the LLS Visionaries community as they lead the charge this Visionaries Action Day. ❤️ Together, we're igniting hope, fueling progress, and transforming futures for #BloodCancer patients and

🎉🌟 Our annual report is here! 🌟🎉

See the stories behind the survivor who relied on our support during their treatment, the scientist putting one of our grants toward new breakthroughs, the patient who can now afford care thanks to our advocacy. And at the heart of it all,

ANOTHER STEP FORWARD! 🎉 The U.S. FDA recently approved a treatment for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

“Finding unique genetic features on cancer cells, like the Philadelphia chromosome, and then designing drugs to

A step forward! 🎉 The U.S. FDA recently approved a treatment for children 1 year and older with CD22-positive B-cell acute lymphoblastic leukemia that has returned or worsened despite earlier treatment.

“LLS support has played a major role in development of antibody-drug

Mark your calendars! 🗓️📌 Join us at our The Leukemia & Lymphoma Society - Policy Advocacy Town Hall Webinar April 25! Get ready to dive deep into the transformative discussions on breaking down financial barriers for cancer patients in 2024 – ensuring that every blood cancer patient receives the life-saving

🎉🌟 Our annual report is here! 🌟🎉

See the stories behind the survivor who relied on our support during their treatment, the scientist putting one of our grants toward new breakthroughs, the patient who can now afford care thanks to our advocacy. And at the heart of it all,

A step forward! 🎉 The U.S. FDA recently approved a treatment for children 1 year and older with CD22-positive B-cell acute lymphoblastic leukemia that has returned or worsened despite earlier treatment.

“LLS support has played a major role in development of antibody-drug